PM1300

N/A

Report date: 2025/07/14 13:31:06

Base Information

Drug NamePM1300
Drug Alias NamePM1300PM-1300
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Receptor tyrosine-protein kinase erbB-3
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companies +[1]  N/A
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhuhai Pumis Biotechnology Co Ltd
Inactive Companies +[1]  N/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A